Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.

Tai W, Gong SL, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Stoch SA, Ma JD.

Drug Metabol Drug Interact. 2013;28(4):217-23. doi: 10.1515/dmdi-2013-0040.

PMID:
24114901
2.

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SD.

Eur J Clin Pharmacol. 2013 Mar;69(3):439-48. doi: 10.1007/s00228-012-1339-x. Epub 2012 Jul 10.

3.
4.

Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Vuppalanchi R, Juluri R, Ghabril M, Kim S, Thong N, Gorski JC, Chalasani N, Hall SD.

J Clin Gastroenterol. 2011 Aug;45(7):638-42. doi: 10.1097/MCG.0b013e3181f8c522.

PMID:
20962670
5.

Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.

Lindamood C, Ortiz S, Shaw A, Rackley R, Gorski JC.

J Clin Pharmacol. 2011 Apr;51(4):575-85. doi: 10.1177/0091270010370846. Epub 2010 May 20.

PMID:
20489028
6.

Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD.

Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2.

7.

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD.

Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6.

PMID:
19420129
8.

Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report.

Malireddy SR, Pinto AG, Chalasani NP, Gorski JC, Hall SD.

Transplant Proc. 2008 Jun;40(5):1789-91. doi: 10.1016/j.transproceed.2008.02.073.

PMID:
18589198
9.

Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.

Dubé MP, Gorski JC, Shen C.

Cardiovasc Toxicol. 2008 Mar;8(1):15-22. doi: 10.1007/s12012-007-9010-y. Epub 2008 Jan 3.

10.

Interaction between midazolam and clarithromycin in the elderly.

Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD.

Br J Clin Pharmacol. 2008 Jan;65(1):98-109. Epub 2007 Jul 17.

11.

Insulin sensitivity is preserved despite disrupted endothelial function.

Shankar SS, Considine RV, Gorski JC, Steinberg HO.

Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E691-6. Epub 2006 May 16.

12.

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD.

Drug Metab Dispos. 2006 Jul;34(7):1208-19. Epub 2006 Apr 12.

PMID:
16611859
13.

Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.

Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge L, Hamilton J, Kishimoto H, Hawes J, Li L, Orschell CM, Srour EF, Blum JS, Donner D, Sledge GW, Nakshatri H, Potter DA.

Clin Cancer Res. 2006 Mar 15;12(6):1883-96.

14.

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.

Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.

Clin Pharmacol Ther. 2006 Mar;79(3):218-30. Epub 2006 Feb 7.

PMID:
16513446
15.

Indinavir impairs endothelial function in healthy HIV-negative men.

Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO.

Am Heart J. 2005 Nov;150(5):933.

PMID:
16290967
16.

Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.

Liangpunsakul S, Kolwankar D, Pinto A, Gorski JC, Hall SD, Chalasani N.

Hepatology. 2005 May;41(5):1144-50.

PMID:
15841467
17.

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.

Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC.

Drug Metab Dispos. 2005 Jul;33(7):1052-5. Epub 2005 Apr 8.

PMID:
15821042
18.

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD.

Clin Pharmacol Ther. 2005 Mar;77(3):178-88.

PMID:
15735612
19.

Effect of cirrhosis and liver transplantation on the gender difference in QT interval.

Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, Chalasani N.

Am J Cardiol. 2005 Mar 1;95(5):691-4.

PMID:
15721125
20.

Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs.

Vereckei A, Gorski JC, Ujhelyi M, Mehra R, Zipes DP.

Cardiovasc Drugs Ther. 2004 Jul;18(4):269-77.

PMID:
15367824
21.

Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.

Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, Preskorn SH.

J Clin Pharmacol. 2004 Oct;44(10):1173-84.

PMID:
15342619
22.

Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.

MacFadyen RJ, Gorski JC, Brater DC, Struthers AD.

Br J Clin Pharmacol. 2004 May;57(5):622-31.

23.

The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD.

Clin Pharmacol Ther. 2004 Jan;75(1):89-100.

PMID:
14749695
24.

The interaction between St John's wort and an oral contraceptive.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.

Clin Pharmacol Ther. 2003 Dec;74(6):525-35.

PMID:
14663455
25.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.

Clin Pharmacol Ther. 2003 Sep;74(3):275-87. Erratum in: Clin Pharmacol Ther. 2004 Mar;75(3):249.

PMID:
12966371
26.

Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.

Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA.

Pharmacogenomics J. 2003;3(2):105-13.

PMID:
12746736
27.
28.

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.

Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW.

Hepatology. 2003 Mar;37(3):544-50.

PMID:
12601351
29.

Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC.

Br J Clin Pharmacol. 2003 Jan;55(1):77-85.

30.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD.

Br J Clin Pharmacol. 2002 Jan;53(1):67-74.

31.

Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.

Asghar A, Gorski JC, Haehner-Daniels B, Hall SD.

Drug Metab Dispos. 2002 Jan;30(1):20-6.

PMID:
11744607
32.

Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.

Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE.

Hepatology. 2001 Dec;34(6):1103-8.

PMID:
11731998
33.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2001 Oct;70(4):317-26.

PMID:
11673747
34.

Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.

Brater DC, Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J.

Trans Am Clin Climatol Assoc. 2001;112:108-15; discussion 116. No abstract available.

35.

In vivo effect of clarithromycin on multiple cytochrome P450s.

Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC.

Drug Metab Dispos. 2001 Jul;29(7):1023-8.

PMID:
11408369
36.

Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.

Chalasani N, Gorski JC, Horlander JC Sr, Craven R, Hoen H, Maya J, Brater DC.

J Am Soc Nephrol. 2001 May;12(5):1010-6.

37.

The effect of hormone replacement therapy on CYP3A activity.

Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD.

Clin Pharmacol Ther. 2000 Oct;68(4):412-7.

PMID:
11061581
38.

Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome.

Agarwal R, Gorski JC, Sundblad K, Brater DC.

J Am Soc Nephrol. 2000 Jun;11(6):1100-5.

39.

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B.

Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

PMID:
10668851
40.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD.

Xenobiotica. 1999 Sep;29(9):931-44.

PMID:
10548453
41.

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.

J Pharmacol Exp Ther. 1999 Sep;290(3):1116-25.

PMID:
10454485
42.

In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.

Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB.

Clin Pharmacol Ther. 1999 Jul;66(1):40-50.

PMID:
10430108
43.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1998 Aug;64(2):133-43.

PMID:
9728893
44.
45.

Role of duration of diuretic effect in preventing sodium retention.

Ferguson JA, Sundblad KJ, Becker PK, Gorski JC, Rudy DW, Brater DC.

Clin Pharmacol Ther. 1997 Aug;62(2):203-8.

PMID:
9284857
46.

Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone.

Gorski JC, Jones DR, Wrighton SA, Hall SD.

Xenobiotica. 1997 Mar;27(3):243-56.

PMID:
9141232
47.

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.

Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1996 Oct;60(4):374-84.

PMID:
8873685
48.

Bimodal distribution of renal cytochrome P450 3A activity in humans.

Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD.

Mol Pharmacol. 1996 Jul;50(1):52-9.

PMID:
8700118
49.

Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity.

Jones DR, Gorski JC, Hamman MA, Hall SD.

J Chromatogr B Biomed Appl. 1996 Mar 29;678(1):105-11.

PMID:
8861660
50.

Supplemental Content

Loading ...
Support Center